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Abstract
Background: ClinicalTrials.gov is a publicly accessible, Internet-based registry of clinical trials managed by the US National
Library of Medicine that has the potential to address selective trial publication. Our objectives were to examine
completeness of registration within ClinicalTrials.gov and to determine the extent and correlates of selective publication.
Methods and Findings: We examined reporting of registration information among a cross-section of trials that had been
registered at ClinicalTrials.gov after December 31, 1999 and updated as having been completed by June 8, 2007, excluding
phase I trials. We then determined publication status among a random 10% subsample by searching MEDLINE using a
systematic protocol, after excluding trials completed after December 31, 2005 to allow at least 2 y for publication following
completion. Among the full sample of completed trials (n=7,515), nearly 100% reported all data elements mandated by
ClinicalTrials.gov, such as intervention and sponsorship. Optional data element reporting varied, with 53% reporting trial
end date, 66% reporting primary outcome, and 87% reporting trial start date. Among the 10% subsample, less than half
(311 of 677, 46%) of trials were published, among which 96 (31%) provided a citation within ClinicalTrials.gov of a
publication describing trial results. Trials primarily sponsored by industry (40%, 144 of 357) were less likely to be published
when compared with nonindustry/nongovernment sponsored trials (56%, 110 of 198; p,0.001), but there was no
significant difference when compared with government sponsored trials (47%, 57 of 122; p=0.22). Among trials that
reported an end date, 75 of 123 (61%) completed prior to 2004, 50 of 96 (52%) completed during 2004, and 62 of 149 (42%)
completed during 2005 were published (p=0.006).
Conclusions: Reporting of optional data elements varied and publication rates among completed trials registered within
ClinicalTrials.gov were low. Without greater attention to reporting of all data elements, the potential for ClinicalTrials.gov to
address selective publication of clinical trials will be limited.
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Selective clinical trial publication, including nonpublication and
delayed publication of completed trials, distorts the evidence
available in the medical literature, compromisingsystematic reviews
and meta-analyses, impairing evidence-based clinical practice, and
undermining guideline recommendations. The extent of selective
publication is not known, but previous studies have estimated
between 25%–50% of supporting trials for US Food and Drug
Administration (FDA)-approved drugs remained unpublished more
than 5 y after approval [1,2]. Similarly unpublished clinical trials of
rosiglitazone [3] identified from a company-maintained websiteand
of erythropoiesis-stimulating agents [4] and antidepressants [5]
found among data submitted to the FDA revealed important
efficacy and safety information to be missing from the medical
literature. Such selective publication is raising questions about the
frequency with which trials are unpublished and how best to ensure
timely public and professional access to all trial results.
Section 113 of the 1997 FDA Modernization Act was enacted in
the United States over 10 y ago to provide the public access to
information about ongoing clinical trials in which they may be
able to participate. The act required the creation of a public
resource for information on studies of drugs, including biological
drug products, which treat ‘‘serious or life-threatening’’ diseases
and conditions conducted under the FDA’s investigational new
drug regulations, mandating the collection of specific descriptive
information pertaining to each clinical trial. In response, the US
National Library of Medicine (NLM) established the Web-based
registry ClinicalTrials.gov in 2000, on behalf of the US National
Institutes of Health (NIH), providing what was intended to be a
publicly available, easily searchable, on-line source of information
for all registered trials, including trials located domestically within
the US and internationally. This registry has the potential to
address selective publication by publicly cataloguing clinical trials
and promoting trial transparency and accountability. In 2004, the
International Committee of Medical Journal Editors (ICMJE)
announced that any clinical trial must be registered by September
2005 in a public clinical trials registry that satisfied several
specifications to be considered for publication in one of its
journals; at that time, only ClinicalTrials.gov met the specifications
put forth by the editors [6]. Between May and October 2005, the
number of trials registered within ClinicalTrials.gov increased by
73% [7].
Despite these efforts, problems with the Web-based registry
have been identified. An audit in 2005 of ClinicalTrials.gov by
investigators at the NLM found one-quarter of registered trials did
not describe the primary outcome defined within the study, and
many of those that did lacked specific information about its timing
and measurement [7]. No published study, however, has
systematically examined the frequency and timeliness with which
results of trials registered within ClinicalTrials.gov are published in
the medical literature, a measure of how well ClinicalTrials.gov
might be addressing selective publication.
The FDA Amendments Act (FDAAA), enacted in September
2007 in the US, included new initiatives to use ClinicalTrials.gov
to further address selective publication. The legislation requires the
sponsors of all drug, biologic, and device trials to register their
studies, at inception, in the publicly available ClinicalTrials.gov
database (with the exception of phase I clinical trials). Moreover,
the registry must be updated to include information on
participants and trial results for approved drugs and devices
within 12 mo of study completion (24 mo if the studied drug is
currently under review at the FDA); specifically, investigators must
report the primary and principal secondary outcome results to
ClinicalTrials.gov for publication within the registry. As details of
legislation implementation remain under negotiation, there is a
need for information about currently registered studies and the
extent of selective publication. While this information is clearly
relevant to policy-makers, it also has profound implications in
terms of the evidence made available for clinicians, researchers,
and patients. Accordingly, our objectives were to determine the
completeness of registrations within ClinicalTrials.gov and deter-
mine the extent and correlates of selective publication.
Methods
Overview
ClinicalTrials.gov uses a Web-based system to facilitate clinical
trial registration by any sponsor, principal investigator, or other
person or organization with primary responsibility for the trial.
Trials are defined by ClinicalTrials.gov as ‘‘… Research studies in
human volunteers to answer specific health questions. Interven-
tional trials determine whether experimental treatments or new
ways of using known therapies are safe and effective under
controlled environments. Observational trials address health issues
in large groups of people or populations in natural settings’’ [8].
ClinicalTrials.gov serves as a registry for trials located both in the
US and internationally and multisite clinical trials that are
conducted using the same protocol are considered one trial in
the registry. ClinicalTrials.gov includes mandatory and optional
data elements (Table S1). Trials cannot be registered without
completion of all mandatory data elements, approval by a human
subject review board (or equivalent), and conformity to the
regulations of the appropriate national health authorities.
Additional information about the registry is available from the
NLM [9].
Study Sample and Variables for Completeness Analysis
Among more than 42,000 trials registered within Clinical-
Trials.gov as of June 2007, we limited our study to clinical trials
that were registered after December 31, 1999 and whose registry
was updated to notify ClinicalTrials.gov that the trial had been
completed as of June 8, 2007, excluding phase I trials (Figure 1). A
completed trial is defined by ClinicalTrials.gov as a study that has
concluded and participants are no longer being examined or
treated (i.e., last patient’s last visit has occurred) [10]. We obtained
information on these trials through a request to the NLM,
requesting the following mandatory data elements for each trial:
identification number, title, primary sponsor, study official, design,
type, phase (if interventional), intervention, condition, and
population studied, along with the following optional data
elements: enrollment, trial start and end dates, primary and
secondary outcome measures, and publication. These data
elements were requested (as opposed to all data elements) because
we determined that each was relevant for identifying publications
of registered trials and for examining associations between
publication and several trial characteristics (e.g., sponsorship,
condition studied). Data from the NLM were provided in a
spreadsheet. Categorizations of data elements are made by study
investigators/sponsors as part of trial registration. For instance,
primary condition studied was assigned to one of 23 categories,
primary study sponsor to one of six. We further categorized
sponsor into three groups: government (US or non-US), industry,
or nongovernment/nonindustry, which included universities,
organizations, foundations, and clinical research networks. We
used study design to categorize study purpose as efficacy only,
efficacy and safety, safety only, or indeterminate. For instance, a
study design of ‘‘Treatment/Randomized/Placebo Control/Safety/
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study design of ‘‘Treatment/Randomized/Placebo Control/Safety
Study’’ was categorized as safety only.
Study Sample and Variables for Publication Analysis
From our full sample of completed trials, we created a 10%
subsample by assigning each trial a random number and selecting
those first in the randomization sequence to determine their
publication status. For this analysis, we also excluded trials with a
registered end date after December 31, 2005, in order to provide
at least a 2 y period within which trials might be published,
consistent with FDAAA legislation. For those trials that did not
provide an end date within ClinicalTrials.gov, but did provide a
start date, we excluded trials for which data collection started after
June 30, 2005 for the same reason. We also excluded trials that
studied complementary and alternative medicine, such as
acupuncture or ginseng, as they were not our focus and we were
concerned that these trials were not appropriate for comparison
with ‘‘traditional’’ biomedical trials.
For all trials within the 10% subsample, we determined the
following: publication status, study type, randomized design, and
study location. Two of three authors (JSR, GKM, EMH)
independently determined the publication status using a search
protocol. All searches began by first examining the ‘‘publication’’
field within ClinicalTrials.gov to determine if trial investigators
provided a citation of an article that described trial results, as this
field is used to display citations of trial results or other relevant
research, as provided by investigators. If no citation was provided,
we then searched MEDLINE using the ClinicalTrials.gov
identification number. If no publication was identified, MEDLINE
was again searched using the intervention, condition studied, and
the principal investigator (when provided in response to the ‘‘study
official’’ field). The articles identified through the search were
matched to the corresponding trial (when possible) using the
following information from ClinicalTrials.gov: description, loca-
tion, enrollment, start and end dates, and primary and secondary
outcome measures. Any differences were resolved by consensus.
Finally, if no publication was identified, we attempted to contact
Figure 1. ClinicalTrials.gov trial inclusion flow chart.
doi:10.1371/journal.pmed.1000144.g001
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if the trial had been published, limiting our attempts to a
maximum of three electronic mail messages.
Once a publication was identified for a registered trial, we
determined whether the primary outcome described in the
manuscript was the same as the primary outcome described
within ClinicalTrials.gov.
Statistical Analysis
We conducted a descriptive analysis, describing data quality,
including completeness of reporting for each data element, and
summarizing the characteristics of our sample by primary sponsor,
type, purpose, phase, location, and condition and population
studied. We then used Chi-square tests to examine the association
between these trial characteristics and publication status. Because
our 10% subsample excluded trials with a registered end date after
December 31, 2005 in order to provide at least 2 y for publication,
but included trials that did not report an end date, we examined
the robustness of our results in two ways. First, we tested the
interaction between end date reporting (yes/no) and each trial
characteristic whose association with publication status was
examined (i.e., sponsor, study location). No trial characteristic
variable interacted significantly with end date reporting. Second,
we repeated our analyses using a time-to-publication approach
among only those trials that reported a trial end date. These
analyses confirmed our main findings. Therefore, only the results
from the full 10% subsample analyses are presented. Statistical
analysis was performed using JMP 7.0.1 and SAS 9.1 (both from
SAS Institute, Inc.). All statistical tests were two-tailed, using a type
I error rate of 0.005 to account for multiple comparisons. Yale
University Human Investigation Committee approval was ob-
tained prior to the study.
Results
Completeness Analyses
There were 7,515 registered clinical trials in our analysis. Nearly
100% of records provided all mandatory data elements: title,
sponsor, condition studied, design, type, phase, and intervention
and population studied. Study official, which is also a mandatory
data element, was also provided by 100% of records, with varying
degrees of specificity: 63% provided the principal investigator
contact name, whereas the others provided another study contact,
such as the name of an institution, company, or facility. Reporting
of optional data elements varied; 82% provided enrollment, 87%
start date, 53% end date, 66% primary outcome measure, and
56% secondary outcome measure(s).
Nearly half of trials (44%) were primarily sponsored by industry,
and cancer was the most common condition studied (13%,
Table 1). Few studies described trials that were conducted only for
safety (4%), although most were described as being conducted for
safety and efficacy (44%). Among interventional trials, 34% were
described as phase III or phase II/III, 31% were phase II or phase
I/II, and 18% were phase IV. More than one-quarter of trials
enrolled children (28%).
Publication Analyses
The random 10% subsample included 752 trials and 75 met at
least one of our additional exclusion criteria (Figure 1). Among 677
included trials, 311 (46%) were published and indexed within
MEDLINE (Table 2). Of these, 215 (69%) did not provide a
citation within ClinicalTrials.gov of an article that described trial
results, whereas 96 (31%) did.
Among the 10% subsample of 677 trials, study end date was not
reported for 309 (46%), although each had its registry updated
within ClinicalTrials.gov to notify officials that the trial had been
completed. Among 368 trials that provided an end date, 123 (33%)
ended prior to 2004, 96 (26%) during 2004, and 149 (40%) during
2005. Trials primarily sponsored by industry, conducted only for
safety, studied cancer, did not include children, and conducted in
both US domestic and international sites were less likely to report
an end date (p,0.005). Trials that reported a study end date were
more likely to be published when compared with trials that did not
(51% versus 40%; relative risk [RR]=1.27, 95% confidence
interval [CI] 1.07–1.50; p=0.005). Among trials that reported an
end date, 75 of 123 (61%) completed prior to 2004, 50 of 96 (52%)
completed during 2004, and 62 of 149 (42%) completed during
2005 were published (p=0.006).
Among the 10% subsample, industry was the primary sponsor
of 357 (53%) trials, government 122 (18%), and nongovernment/
nonindustry 198 (29%). Trials primarily sponsored by industry
were less likely to be published when compared with nongovern-
ment/nonindustry sponsored trials (40% versus 56%; RR=0.73,
95% CI 0.61–0.87; p,0.001); there was no statistically significant
difference in publication rates between industry and government
primary sponsored trials (40% versus 47%; p=0.22). Among
government sponsored trials, only 42% of those primarily
sponsored by the NIH were published (30 of 74). Among industry
sponsors with ten or more trials in our subsample, publication
rates varied widely: 13 of 14 (93%) trials primarily sponsored by
Merck, seven of 11 (64%) by Amgen, and 15 of 24 (63%) by
Johnson & Johnson were published, whereas only seven of 27
(26%) trials primarily sponsored by Novartis, nine of 34 (27%) by
GlaxoSmithKline, and four of 14 (29%) by Sanofi-Aventis were
published.
Among the 10% subsample, 248 (37%) trials compared an
intervention with placebo (89% were randomized), 224 (33%)
compared an intervention with another active agent (92% were
randomized), 138 (20%) examined an intervention without a
comparison group, and 67 (10%) were observational (no
intervention). Trials comparing an intervention with placebo were
more likely to be published when compared with other trial
designs (56% versus 40%; RR=1.42, 95% CI 1.21–1.66;
p,0.001), and phase II trials were less likely to be published
when compared with phase III or phase IV trials (36% versus
50%; RR=0.72, 95% CI 0.58–0.90; p=0.002). Other examined
trial characteristics were not significantly associated with publica-
tion: condition or population studied, study purpose or location, or
trial size.
Among 311 published trials, 198 (64%) reported a primary
outcome within ClinicalTrials.gov, nearly all of which (97%)
matched the primary outcome measure in the published
manuscript. However, the data quality varied markedly, particu-
larly its degree of specificity with regards to providing the time
period after which the outcome will be studied and how the
outcome will be measured. As an example, one trial reported the
primary outcome ‘‘change from baseline to 6-mo in distal femur
bone mineral density,’’ while another reported ‘‘bone mineral
density.’’
Discussion
Our study demonstrates that the potential of ClinicalTrials.gov
registry to address selective publication and better inform the
public and professionals about the results from completed clinical
trials is limited because critical information from trial registration,
such as study contact, trial end date, and primary outcome, were
Trial Publication and ClinicalTrials.Gov
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completed trials registered within ClinicalTrials.gov were low,
even among trials with at least 4 y documented since study
completion. Low publication rates were widespread among
differing trial sponsors, conditions studied, study types, and
locations. However, we also found significantly different publica-
tion rates among study types and primary sponsors, consistent with
prior research [11]. Even when trials were found to be published,
for the majority the citation was not available within Clinical-
Trials.gov, which would have made it easy for the public and
professionals to access results.
We expected that the trials we examined were likely to have
been published in that they were recently completed after being
registered at ClinicalTrials.gov within the past decade, ensuring
that thet trial was in compliance with ICMJE requirements if the
results were publishable. However, the recent nature of our sample
is a possible explanation for our finding low rates of trial
publication. Although we allowed at least 2 y after the study
ended for publication, consistent with FDAAA legislation, rates
were higher among those that ended longer ago. Nevertheless,
publication rates reached only 60% among trials documented as
having ended prior to 2004, an allowance of at least 4 y for trial
publication. Importantly, all the trials included in our study had
their registration updated to notify ClinicalTrials.gov that the trial
had been completed.
Many studies have attempted to evaluate the extent of selective
publication in the biomedical literature and found similarly low
rates of publication [5,12–24], although none have used, to our
knowledge, as large and as broadly representative a registry as
ClinicalTrials.gov, particularly with regards to condition studied
and study location, with the exception of two recent studies
focused on the publication of trials submitted to the FDA [1,2].
Other evidence concerning selective publication is anecdotal, such
as the absence of 6 mo of trial data from a key publication
describing the efficacy of celecoxib [25,26], the delay of
publication for two early trials of rofecoxib until after the
medication was withdrawn from the market [27–29], and the
aforementioned studies of rosiglitazone [3], erythropoiesis-stimu-
lating agents [4], and antidepressants [5].
However, as described, low publications rates were not limited
to specific trial sponsors, suggesting that selective publication is an
issue among trials sponsored by both industry and government
and reinforcing the importance of registries like ClinicalTrials.gov
for addressing this problem. Selective publication may occur for
several reasons, although our study was not designed to evaluate its
causes. If trial results put either investigators or the study’s sponsor
Table 1. Characteristics of completed trials registered in the ClinicalTrials.gov database after December 31, 1999 (excluding phase
I trials).
Trial Characteristic n (%)
a (n=7,515)
Sponsor Industry 3,330 (44%)
Nongovernment/Nonindustry 2,824 (38%)
Government (US and non-US) 1,361 (18%)
Condition studied Cancers and other neoplasms 973 (13)
Behaviors and mental disorders 727 (10)
Heart and blood diseases 727 (10)
Nutritional and metabolic diseases 687 (9)
Conditions of the urinary tract and sexual organs, and pregnancy 522 (7)
Viral diseases 467 (6)
Nervous system diseases 461 (6)
Respiratory tract (lung and bronchial) diseases 363 (5)
Bacterial and fungal diseases 260 (4)
Other 2,328 (31)
Study purpose Safety and efficacy 3,304 (44)
Efficacy only 1,737 (23)
Safety only 297 (4)
Indeterminate 2,177 (29)
Study type Interventional 6,674 (89)
Observational 841 (11)
Study phase
b Phase I/phase II or phase II 2,059 (31)
Phase II/phase III or phase III 2,295 (34)
Phase IV 1,110 (17)
Not applicable 1,209 (18)
Population studied Included adults 6,850 (91)
Included older adults (age $65 y) 5,468 (73)
Included children 2,076 (28)
aProportions may not sum to 100 because of rounding.
bData element is only required to be reported for interventional studies (n=6,674).
doi:10.1371/journal.pmed.1000144.t001
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ClinicalTrials.gov database.
Trial Characteristic n of Trials Published/Total n (%) p-Value
Overall 311/677 (46) —
Sponsor — 0.003*
Industry 144/357 (40) —
Nongovernment/nonindustry 110/198 (56) —
Government agencies (US and non-US) 57/122 (47) —
NIH (US) 30/74 (41) —
US federal agency, excluding NIH 19/34 (56) —
Government, excluding US federal 8/14 (57) —
Condition studied — 0.23
Cancers and other neoplasms 43/102 (42) —
Behaviors and mental disorders 33/62 (53) —
Heart and blood diseases 22/46 (48) —
Nutritional and metabolic diseases 24/52 (46) —
Conditions of the urinary tract and sexual organs, and pregnancy 24/43 (56) —
Viral diseases 18/54 (33) —
Nervous system diseases 21/44 (48) —
Respiratory tract (lung and bronchial) diseases 13/40 (33) —
Bacterial and fungal diseases 22/40 (55) —
Other 91/194 (47) —
Study purpose — 0.23
Safety and efficacy 139/307 (45) —
Efficacy only 71/133 (53) —
Safety only 12/31 (39) —
Indeterminate 89/206 (43) —
Study type — ,0.001
**
Comparison: intervention with placebo 140/248 (56) —
Randomization? — 0.75
Yes 124/221 (56) —
No 16/27 (59) —
Comparison: intervention with other active agent 96/224 (43) —
Randomization? — 0.17
Yes 85/205 (41) —
No 11/19 (58) —
No comparison: intervention alone 47/138 (34) —
Observational (no intervention) 28/67 (42) —
Study phase
a — 0.008
Phase I/phase II or phase II 66/184 (36) —
Phase II/phase III or phase III 114/235 (49) —
Phase IV 57/109 (52) —
Trial size
b — 0.37
$160 Participants 131/283 (46) —
,160 Participants 120/282 (43) —
Population studied — —
Included older adults ($65 y) 230/499 (46) 0.89
c
Included children (,18 y) 82/194 (42) 0.22
|d
Study location — 0.30
US/Canada only 148/339 (44) —
US/Canada and international 20/43 (47) —
International only 87/192 (45) —
Trial Publication and ClinicalTrials.Gov
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addition, if trial results contradict investigators’ beliefs, providing
unexpected support (or lack of support) for a particular clinical
practice, they may not be submitted for publication [30]. This may
be exacerbated by investigator reluctance to publish negative
results given the need to highlight ‘‘positive, promising’’ findings
for grant applications. Finally, researchers, reviewers, and editors
have historically been more enthusiastic about positive or
equivalence trials and less excited about negative trials [6];
accordingly, these latter trials are submitted and accepted for
publication less often [14–16,21,31]. Suggestive of this, 70% of
published manuscripts in our study from intervention-placebo or
intervention-active trials were reported as positive, although we
are unable to determine what proportion of the unpublished trials
found positive results.
Although the FDAAA now requires reporting of trial results
within 1 to 2 y after study completion within ClinicalTrials.gov,
selective publication may not be fully remedied. The quality of the
information provided for some data elements within Clinical-
Trials.gov varied widely. It is not clear whether or how often the
accuracy of the data is verified by the NLM, although those
responsible for the conduct of the clinical trial are principally
accountable for its quality and accuracy. Even though nearly all
trials reported mandatory data elements, many entries were of
poor quality and provided limited information, particularly the
principal investigator/study contact. Reporting of optional data
elements ranged widely and, similar to the mandatory data
elements, many were of poor quality and provided limited
information. As had been shown in prior research [7], only 66%
of trials reported their primary outcome measure, and outcomes
were often vague and poorly specific among those that did, making
it difficult or impossible to detect outcome reporting bias. Given
the documented presence of outcome reporting bias among trials
studied in other settings [5,12,13], the potential impact of
ClinicalTrials.gov on outcome reporting bias deserves further
research. Just as significant progress has been made with regards to
improved reporting of the study intervention (i.e., drug name)
within ClinicalTrials.gov [32], progress can be made by
mandating the registration of all information that is necessary
for the public and profession to access and interpret trial results,
including primary and secondary outcomes, study location, and
enrollment, with clear field requirements to prevent vague
reporting and improve data quality. Furthermore, we propose
that either the NLM or another specified agency be given
sufficient power of enforcement, including the capacity to assess
fines or other penalties to sponsors or investigators who are not
compliant with requirements.
One limitation of our study was that nearly half of the 10%
subsample of trials among which we determined publication status
did not report a trial end date, and those that did not were
published at the lowest rates, preventing an assurance that all trials
were allowed at least 2 y after study completion for trial
publication. In addition, although all the trials included in our
study had their registries updated to notify ClinicalTrials.gov that
the trial had been completed, the date on which this specific
notification was made was not available. This low rate of reporting
of an optional data element (‘‘study end date’’) in itself suggests
that reporting of information needed to comprehensively assess
trial progress and completion must be required and verified. In
addition, we cannot be certain of the relationship between not
reporting trial end date and publication. Not reporting an end date
may indicate that study officials had determined that the trial
would not be submitted for publication and thus made minimal
efforts to fully update the trial’s registration within ClinicalTrials.-
gov, such as by providing the actual trial end date, outside of
providing notification that the trial had been completed. Similarly,
the low response rate among investigators surveyed about
completed yet unpublished registered trials may indicate that the
trials were not published and investigators were instead focused on
current study efforts. Nevertheless, rates of publication were low
among both trials that did and did not report end dates.
There are other limitations to our study. Relevant publications
may not have been identified in our review, partly because we
limited our study to MEDLINE and did not search other
databases, such as EMBASE or research conference proceedings
(abstracts). However, EMBASE is not publicly accessible,
requiring a subscription for access. Moreover, research abstracts
are often preliminary and rarely provide all relevant efficacy and
safety findings. Our search for publications was extensive,
involving two independent investigators using a systematic method
to query MEDLINE. If we were unable to identify a trial
publication, it is unlikely that others using PubMed to find results
Trial Characteristic n of Trials Published/Total n (%) p-Value
Not provided 56/103 (54) —
Trial end date — 0.005
***
No end date provided 124/309 (40) —
End date provided 187/368 (51) —
Before January 1, 2004 75/123 (61) —
Between January 1, 2004 and December 31, 2004 (inclusive) 50/96 (52) —
Between January 1, 2005 and December 31, 2005 (inclusive) 62/149 (42) —
*p-Value for Pearson Chi-square testing the null hypothesis that publication rates among industry, government, and nonindustry/nongovernment sponsored trials are
no different.
**p-Value for Pearson Chi-square testing the null hypothesis that publication rates among trials that compared an intervention with placebo, trials that compared an
intervention with another active agent, trials with no comparison, and observational studies are no different.
***p-Value for Pearson Chi-square testing the null hypothesis that publication rates among trials with and without end dates provided are no different.
aAmong interventional trials that reported a trial phase only.
bThe median trial sample size was 160.
cIn comparison with trials that did not include older adults.
dIn comparison with trials that did not include children.
doi:10.1371/journal.pmed.1000144.t002
Table 2. Cont.
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do so. In addition, some studies may have been made publicly
available elsewhere. In response to criticism about selective
publication, several pharmaceutical companies and their US trade
association (Pharmaceutical Research and Manufacturers of
America) have established registries to report results of their
clinical trials [33–36]. Although a useful step, these registries do
not adequately address the issue of selective publication since the
results are not subject to peer review and provide no assurance of
complete reporting of efficacy and safety. Secondly, our sample
size may have been too small for our analyses to have sufficient
power to identify true differences in publication rates between trial
subcategories, such as sponsorship or study purpose. Finally, many
changes may have already been or will be made to Clinical-
Trials.gov in response to addressing the new requirements enacted
as part of the FDAAA. However, an important purpose of our
study was to inform these efforts and future work will need to
examine whether changes made the registry more effective.
The scientific community should be prioritizing the timely and
accurate publication and dissemination of clinical trial results,
regardless of the strength and direction of trial results. Current, up-
to-date evidence is critical for clinicians, researchers, and patients,
and late publication can impair and undermine evidence-based
clinical practice almost as effectively as nonpublication. In
addition, investigators have an obligation to ensure that the efforts
of patients who volunteer as trial subjects are shared to advance
science. Publication rates among completed trials registered within
ClinicalTrials.gov were low, even among trials with at least 4 y
since the study had ended. Critically, even among published trials,
few reported the citation within ClinicalTrials.gov, a small but
necessary step that should be required in order to make it easy for
the public and the profession to have access to the trial results. The
FDA needs a coordinated strategy for oversight and enforcement
of the new requirements of the FDAAA, along with a commitment
from industry, government, and all other trial sponsors, as well as
the scientific community, to minimize selective publication of trials
and ensure timely public and professional access to trial results.
Supporting Information
Table S1 ClinicalTrials.gov mandatory and optional data
elements for intervention trials.
Found at: doi:10.1371/journal.pmed.1000144.s001 (0.07 MB
DOC)
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Background. People assume that whenever they are ill,
health care professionals will make sure they get the best
available treatment. But how do clinicians know which
treatment is most appropriate? In the past, clinicians used
their own experience to make treatment decisions.
Nowadays, they rely on evidence-based medicine—the
systematic review and appraisal of the results of clinical
trials, studies that investigate the efficacy and safety of
medical interventions in people. However, evidence-based
medicine can only be effective if all the results from clinical
trials are published promptly in medical journals.
Unfortunately, the results of trials in which a new drug did
not perform better than existing drugs or in which it had
unwanted side effects often remain unpublished or only
appear in the public domain many years after the drug has
been approved for clinical use by the US Food and Drug
Administration (FDA) and other governmental bodies.
Why Was This Study Done? The extent of this ‘‘selective’’
publication, which can impair evidence-based clinical
practice, remains unclear but is thought to be substantial.
In this study, the researchers investigate the problem of
selective publication by systematically examining the extent
of publication of the results of trials registered in
ClinicalTrials.gov, a Web-based registry of US and
international clinical trials. ClinicalTrials.gov was established
in 2000 by the US National Library of Medicine in response to
the 1997 FDA Modernization Act. This act required
preregistration of all trials of new drugs to provide the
public with information about trials in which they might be
able to participate. Mandatory data elements for registration
in ClinicalTrials.gov initially included the trial’s title, the
condition studied in the trial, the trial design, and the
intervention studied. In September 2007, the FDA
Amendments Act expanded the mandatory requirements
for registration in ClinicalTrials.gov by making it necessary,
for example, to report the trial start date and to report
primary and secondary outcomes (the effect of the
intervention on predefined clinical measurements) in the
registry within 2 years of trial completion.
What Did the Researchers Do and Find? The researchers
identified 7,515 trials that were registered within
ClinicalTrials.gov after December 31, 1999 (excluding phase
I, safety trials), and whose record indicated trial completion
by June 8, 2007. Most of these trials reported all the
mandatory data elements that were required by
ClinicalTrials.gov before the FDA Amendments Act but
reporting of optional data elements was less complete. For
example, only two-thirds of the trials reported their primary
outcome. Next, the researchers randomly selected 10% of
the trials and, after excluding trials whose completion date
was after December 31, 2005 (to allow at least two years for
publication), determined the publication status of this
subsample by systematically searching MEDLINE (an online
database of articles published in selected medical and
scientific journals). Fewer than half of the trials in the
subsample had been published, and the citation for only a
third of these publications had been entered into
ClinicalTrials.gov. Only 40% of industry-sponsored trials had
been published compared to 56% of nonindustry/
nongovernment-sponsored trials, a difference that is
unlikely to have occurred by chance. Finally, 61% of trials
with a completion date before 2004 had been published, but
only 42% of trials completed during 2005 had been
published.
What Do These Findings Mean? These findings indicate
that, over the period studied, critical trial information was
not included in the ClinicalTrials.gov registry. The FDA
Amendments Act should remedy some of these
shortcomings but only if the accuracy and completeness of
the information in ClinicalTrials.gov is carefully monitored.
These findings also reveal that registration in
ClinicalTrials.gov does not guarantee that trial results will
appear in a timely manner in the scientific literature.
However, they do not address the reasons for selective
publication (which may be, in part, because it is harder to
publish negative results than positive results), and they are
potentially limited by the methods used to discover whether
trial results had been published. Nevertheless, these findings
suggest that the FDA, trial sponsors, and the scientific
community all need to make a firm commitment to minimize
the selective publication of trial results to ensure that
patients and clinicians have access to the information they
need to make fully informed treatment decisions.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000144.
N PLoS Medicine recently published two related articles on
selected publication by Ida Sim and colleagues and by Lisa
Bero and colleagues and an editorial discussing the FDA
Amendments Act
N ClinicalTrials.gov provides information about the US
National Institutes of Health clinical trial registry, including
background information about clinical trials, and a fact
sheet detailing the requirements of the FDA Amendments
Act 2007 for trial registration
N The US Food and Drug Administration provides further
information about drug approval in the US for consumers
and health care professionals
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